Functional roles of alternative splicing factors in human disease

Alternative splicing (AS) is an important mechanism used to generate greater transcriptomic and proteomic diversity from a finite genome. Nearly all human gene transcripts are alternatively spliced and can produce protein isoforms with divergent and even antagonistic properties that impact cell functions. Many AS events are tightly regulated in a cell‐type or tissue‐specific manner, and at different developmental stages. AS is regulated by RNA‐binding proteins, including cell‐ or tissue‐specific splicing factors. In the past few years, technological advances have defined genome‐wide programs of AS regulated by increasing numbers of splicing factors. These splicing regulatory networks (SRNs) consist of transcripts that encode proteins that function in coordinated and related processes that impact the development and phenotypes of different cell types. As such, it is increasingly recognized that disruption of normal programs of splicing regulated by different splicing factors can lead to human diseases. We will summarize examples of diseases in which altered expression or function of splicing regulatory proteins has been implicated in human disease pathophysiology. As the role of AS continues to be unveiled in human disease and disease risk, it is hoped that further investigations into the functions of numerous splicing factors and their regulated targets will enable the development of novel therapies that are directed at specific AS events as well as the biological pathways they impact. WIREs RNA 2015, 6:311–326. doi: 10.1002/wrna.1276

[1]  D. Bates,et al.  Hallmarks of alternative splicing in cancer , 2014, Oncogene.

[2]  N. Norton,et al.  Identification of Novel Mutations in RBM20 in Patients with Dilated Cardiomyopathy , 2010, Clinical and translational science.

[3]  Yi Xing,et al.  An ESRP‐regulated splicing programme is abrogated during the epithelial–mesenchymal transition , 2010, The EMBO journal.

[4]  T. Cooper,et al.  Disruption of splicing regulated by a CUG-binding protein in myotonic dystrophy. , 1998, Science.

[5]  N. Rajewsky,et al.  RNA-binding protein RBM20 represses splicing to orchestrate cardiac pre-mRNA processing. , 2014, The Journal of clinical investigation.

[6]  Kenny Q. Ye,et al.  Strong Association of De Novo Copy Number Mutations with Autism , 2007, Science.

[7]  T. Cooper,et al.  Pre-mRNA splicing in disease and therapeutics. , 2012, Trends in molecular medicine.

[8]  R. Carstens,et al.  Exo70 isoform switching upon epithelial-mesenchymal transition mediates cancer cell invasion. , 2013, Developmental cell.

[9]  Monika Heiner,et al.  The RNA-Binding Protein QKI Suppresses Cancer-Associated Aberrant Splicing , 2014, PLoS genetics.

[10]  B. Spencer‐Dene,et al.  An important role for the IIIb isoform of fibroblast growth factor receptor 2 (FGFR2) in mesenchymal-epithelial signalling during mouse organogenesis. , 2000, Development.

[11]  E. Thompson,et al.  Cancer: The to and fro of tumour spread , 2013, Nature.

[12]  G. Christofori,et al.  The RNA-binding protein Rbfox2: an essential regulator of EMT-driven alternative splicing and a mediator of cellular invasion , 2014, Oncogene.

[13]  Lili Wan,et al.  RNA and Disease , 2009, Cell.

[14]  J. Ule,et al.  Characterizing the RNA targets and position-dependent splicing regulation by TDP-43. , 2011, Nature neuroscience.

[15]  Thomas Tuschl,et al.  Identification of RNA–protein interaction networks using PAR‐CLIP , 2012, Wiley interdisciplinary reviews. RNA.

[16]  Brent L Fogel,et al.  Orchestration of neurodevelopmental programs by RBFOX1: implications for autism spectrum disorder. , 2013, International review of neurobiology.

[17]  Claude C. Warzecha,et al.  ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing. , 2009, Molecular cell.

[18]  Neelroop Parikshak,et al.  RBFOX1 regulates both splicing and transcriptional networks in human neuronal development. , 2012, Human molecular genetics.

[19]  Li-Huei Tsai,et al.  ALS-associated mutation FUS-R521C causes DNA damage and RNA splicing defects. , 2014, The Journal of clinical investigation.

[20]  J. Manley,et al.  Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. , 2010, Genes & development.

[21]  T. Cooper,et al.  CUGBP1 overexpression in mouse skeletal muscle reproduces features of myotonic dystrophy type 1. , 2010, Human molecular genetics.

[22]  Eric T. Wang,et al.  Alternative Isoform Regulation in Human Tissue Transcriptomes , 2008, Nature.

[23]  Gene W. Yeo,et al.  ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43 , 2013, Proceedings of the National Academy of Sciences.

[24]  Lior Pachter,et al.  Exon-Level Microarray Analyses Identify Alternative Splicing Programs in Breast Cancer , 2010, Molecular Cancer Research.

[25]  Kevin F. Bieniek,et al.  Unconventional Translation of C9ORF72 GGGGCC Expansion Generates Insoluble Polypeptides Specific to c9FTD/ALS , 2013, Neuron.

[26]  Wenjun Guo,et al.  The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.

[27]  Melissa S Jurica,et al.  Pre-mRNA splicing: awash in a sea of proteins. , 2003, Molecular cell.

[28]  Claude C. Warzecha,et al.  Complex changes in alternative pre-mRNA splicing play a central role in the epithelial-to-mesenchymal transition (EMT). , 2012, Seminars in cancer biology.

[29]  Michael Q. Zhang,et al.  HITS-CLIP and integrative modeling define the Rbfox splicing-regulatory network linked to brain development and autism. , 2014, Cell reports.

[30]  A. Chadli THE CANCER CELL , 1924, La Presse medicale.

[31]  M. LeWinter,et al.  Titin is a major human disease gene. , 2013, Circulation.

[32]  R. Weinberg,et al.  Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. , 2012, Seminars in cancer biology.

[33]  G. Berx,et al.  Regulatory networks defining EMT during cancer initiation and progression , 2013, Nature Reviews Cancer.

[34]  A. Krainer,et al.  THE SPLICING FACTOR SRSF1 REGULATES APOPTOSIS AND PROLIFERATION TO PROMOTE MAMMARY EPITHELIAL CELL TRANSFORMATION , 2011, Nature Structural &Molecular Biology.

[35]  David Heckerman,et al.  A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD , 2011, Neuron.

[36]  R. Huang,et al.  Epithelial-Mesenchymal Transitions in Development and Disease , 2009, Cell.

[37]  Bruce L. Miller,et al.  Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS , 2011, Neuron.

[38]  Christopher R. Sibley,et al.  iCLIP: Protein–RNA interactions at nucleotide resolution , 2014, Methods.

[39]  Richard L Moss,et al.  Mutation that dramatically alters rat titin isoform expression and cardiomyocyte passive tension. , 2008, Journal of molecular and cellular cardiology.

[40]  Robert H. Brown,et al.  Partial loss of TDP-43 function causes phenotypes of amyotrophic lateral sclerosis , 2014, Proceedings of the National Academy of Sciences.

[41]  Xun Hu,et al.  Mutations in FUS, an RNA Processing Protein, Cause Familial Amyotrophic Lateral Sclerosis Type 6 , 2009, Science.

[42]  Kenneth S. Campbell,et al.  Titin isoform changes in rat myocardium during development , 2004, Mechanisms of Development.

[43]  P. Comoglio,et al.  A splicing variant of the RON transcript induces constitutive tyrosine kinase activity and an invasive phenotype , 1996, Molecular and cellular biology.

[44]  P. Pellikka,et al.  Mutations in ribonucleic acid binding protein gene cause familial dilated cardiomyopathy. , 2009, Journal of the American College of Cardiology.

[45]  J. Manley,et al.  Mechanisms of alternative splicing regulation: insights from molecular and genomics approaches , 2009, Nature Reviews Molecular Cell Biology.

[46]  H. Ford,et al.  Mammary Gland Studies as Important Contributors to the Cause of Epithelial Mesenchymal Plasticity in Malignancy , 2010, Journal of Mammary Gland Biology and Neoplasia.

[47]  Jeffrey M. Rosen,et al.  Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features , 2009, Proceedings of the National Academy of Sciences.

[48]  Jian Zhang,et al.  Misregulation of pre-mRNA alternative splicing in cancer. , 2013, Cancer discovery.

[49]  D. Cleveland,et al.  Understanding the role of TDP-43 and FUS/TLS in ALS and beyond , 2011, Current Opinion in Neurobiology.

[50]  A. Ludolph,et al.  Amyotrophic lateral sclerosis. , 2012, Current opinion in neurology.

[51]  Jing Yang,et al.  Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. , 2012, Cancer cell.

[52]  Istvan Mody,et al.  The splicing regulator Rbfox1 (A2BP1) controls neuronal excitation in the mammalian brain , 2011, Nature Genetics.

[53]  Stephanie C Huelga,et al.  Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs , 2012, Nature Neuroscience.

[54]  T. Cooper,et al.  MicroRNAs coordinate an alternative splicing network during mouse postnatal heart development. , 2010, Genes & development.

[55]  Robert B Darnell,et al.  HITS‐CLIP: panoramic views of protein–RNA regulation in living cells , 2010, Wiley interdisciplinary reviews. RNA.

[56]  Renal Division,et al.  The epithelial splicing factors esRp1 and esRp2 positively and negatively regulate diverse types of alternative splicing events , 2009 .

[57]  P. Ellinor,et al.  RBM20, a gene for hereditary cardiomyopathy, regulates titin splicing , 2012, Nature Medicine.

[58]  R. Padgett New connections between splicing and human disease. , 2012, Trends in genetics : TIG.

[59]  Colin N. Dewey,et al.  Rbm20 regulates titin alternative splicing as a splicing repressor , 2013, Nucleic acids research.

[60]  M. Nieto,et al.  Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. , 2012, Cancer cell.

[61]  Nicholas C. Flytzanis,et al.  An EMT–Driven Alternative Splicing Program Occurs in Human Breast Cancer and Modulates Cellular Phenotype , 2011, PLoS genetics.

[62]  F. Rousset,et al.  RBFOX2 Is an Important Regulator of Mesenchymal Tissue-Specific Splicing in both Normal and Cancer Tissues , 2012, Molecular and Cellular Biology.

[63]  B. Frey,et al.  Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing , 2008, Nature Genetics.

[64]  M. Cazzola,et al.  The genetic basis of myelodysplasia and its clinical relevance. , 2013, Blood.

[65]  Chonghui Cheng,et al.  Alternative RNA splicing and cancer , 2013, Wiley interdisciplinary reviews. RNA.

[66]  C. Guthrie,et al.  Mechanical Devices of the Spliceosome: Motors, Clocks, Springs, and Things , 1998, Cell.

[67]  Chonghui Cheng,et al.  CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. , 2011, The Journal of clinical investigation.

[68]  B. Blencowe,et al.  Global Profiling and Molecular Characterization of Alternative Splicing Events Misregulated in Lung Cancer , 2010, Molecular and Cellular Biology.

[69]  C. Ghigna,et al.  Sam68 regulates EMT through alternative splicing–activated nonsense-mediated mRNA decay of the SF2/ASF proto-oncogene , 2010, The Journal of cell biology.

[70]  C. Thompson,et al.  bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death , 1993, Cell.

[71]  J. Castle,et al.  A postnatal switch of CELF and MBNL proteins reprograms alternative splicing in the developing heart , 2008, Proceedings of the National Academy of Sciences.

[72]  M. Tatari,et al.  EMT as the ultimate survival mechanism of cancer cells. , 2012, Seminars in cancer biology.

[73]  J. Ule,et al.  Hexanucleotide Repeats in ALS/FTD Form Length-Dependent RNA Foci, Sequester RNA Binding Proteins, and Are Neurotoxic , 2013, Cell reports.

[74]  S. Horvath,et al.  Transcriptomic Analysis of Autistic Brain Reveals Convergent Molecular Pathology , 2011, Nature.

[75]  J. Valcárcel,et al.  RBM5, 6, and 10 differentially regulate NUMB alternative splicing to control cancer cell proliferation. , 2013, Molecular cell.

[76]  M. Swanson,et al.  Reversal of RNA missplicing and myotonia after muscleblind overexpression in a mouse poly(CUG) model for myotonic dystrophy. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[77]  Gene W. Yeo,et al.  Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43 , 2011, Nature Neuroscience.

[78]  Bruce L. Miller,et al.  Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis , 2006, Science.

[79]  J. Rothstein,et al.  RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia , 2013, Proceedings of the National Academy of Sciences.

[80]  A. Krainer,et al.  The gene encoding the splicing factor SF2/ASF is a proto-oncogene , 2007, Nature Structural &Molecular Biology.

[81]  S. Richard,et al.  Sam68 sequestration and partial loss of function are associated with splicing alterations in FXTAS patients , 2010, The EMBO journal.

[82]  A. Krainer,et al.  Listening to silence and understanding nonsense: exonic mutations that affect splicing , 2002, Nature Reviews Genetics.

[83]  A. Mele,et al.  Loss of the multifunctional RNA-binding protein RBM47 as a source of selectable metastatic traits in breast cancer , 2014, eLife.

[84]  M. Ares,et al.  Muscleblind-like 2-Mediated Alternative Splicing in the Developing Brain and Dysregulation in Myotonic Dystrophy , 2012, Neuron.

[85]  R. J. White,et al.  Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat. , 2000, Science.

[86]  C. van Broeckhoven,et al.  Pathological mechanisms underlying TDP-43 driven neurodegeneration in FTLD–ALS spectrum disorders , 2013, Human molecular genetics.

[87]  Michael G. Poulos,et al.  Developments in RNA splicing and disease. , 2011, Cold Spring Harbor perspectives in biology.

[88]  C. Will,et al.  Identification of both shared and distinct proteins in the major and minor spliceosomes. , 1999, Science.

[89]  C. Ghigna,et al.  Making alternative splicing decisions during epithelial-to-mesenchymal transition (EMT) , 2012, Cellular and Molecular Life Sciences.

[90]  P. Hagerman,et al.  Advances in clinical and molecular understanding of the FMR1 premutation and fragile X-associated tremor/ataxia syndrome , 2013, The Lancet Neurology.

[91]  M. Swanson,et al.  RNA–protein interactions in unstable microsatellite diseases , 2014, Brain Research.

[92]  Dan M Roden,et al.  Whole Exome Sequencing Identifies a Causal RBM20 Mutation in a Large Pedigree With Familial Dilated Cardiomyopathy , 2013, Circulation. Cardiovascular genetics.

[93]  S. Stamm,et al.  Function of Alternative Splicing , 2004 .

[94]  O. Hardiman,et al.  Amyotrophic lateral sclerosis , 2011, The Lancet.

[95]  A. Leutenegger,et al.  Association of TALS Developmental Disorder with Defect in Minor Splicing Component U4atac snRNA , 2011, Science.

[96]  Guey-Shin Wang,et al.  Increased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation. , 2007, Molecular cell.

[97]  M. Looso,et al.  RBM24 is a major regulator of muscle-specific alternative splicing. , 2014, Developmental cell.

[98]  Michael R Green,et al.  Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene. , 2005, Molecular cell.

[99]  J L Haines,et al.  Supporting Online Material Materials and Methods Figs. S1 to S7 Tables S1 to S4 References Mutations in the Fus/tls Gene on Chromosome 16 Cause Familial Amyotrophic Lateral Sclerosis , 2022 .

[100]  Jason I. Herschkowitz,et al.  Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer , 2010, Breast Cancer Research.

[101]  Jane Y. Wu,et al.  Pre-mRNA splicing and retinitis pigmentosa. , 2006, Molecular vision.

[102]  Michael Q. Zhang,et al.  Defining the regulatory network of the tissue-specific splicing factors Fox-1 and Fox-2. , 2008, Genes & development.

[103]  Alessandra Montecucco,et al.  The alternative splicing side of cancer. , 2014, Seminars in cell & developmental biology.

[104]  M. D. Del Bigio,et al.  Neuronal intranuclear inclusions in a new cerebellar tremor/ataxia syndrome among fragile X carriers. , 2002, Brain : a journal of neurology.

[105]  Christa Lese Martin,et al.  Cytogenetic and molecular characterization of A2BP1/FOX1 as a candidate gene for autism , 2007, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[106]  W. Hauswirth,et al.  A Muscleblind Knockout Model for Myotonic Dystrophy , 2003, Science.

[107]  Matthew J. Brauer,et al.  Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. , 1994, Science.

[108]  M. Nieto,et al.  The ins and outs of the epithelial to mesenchymal transition in health and disease. , 2011, Annual review of cell and developmental biology.

[109]  Ji Wan,et al.  Genome-Wide Determination of a Broad ESRP-Regulated Posttranscriptional Network by High-Throughput Sequencing , 2012, Molecular and Cellular Biology.

[110]  Auinash Kalsotra,et al.  Functional consequences of developmentally regulated alternative splicing , 2011, Nature Reviews Genetics.

[111]  Chonghui Cheng,et al.  Cell type-restricted activity of hnRNPM promotes breast cancer metastasis via regulating alternative splicing , 2014, Genes & development.

[112]  H. Ford,et al.  Breast cancer epithelial-to-mesenchymal transition: examining the functional consequences of plasticity , 2011, Breast Cancer Research.

[113]  D. Baralle,et al.  Splicing in action: assessing disease causing sequence changes , 2005, Journal of Medical Genetics.

[114]  A. Kramer,et al.  Effect of a rapid response system for patients in shock on time to treatment and mortality during 5 years* , 2007, Critical care medicine.

[115]  Guey-Shin Wang,et al.  Splicing in disease: disruption of the splicing code and the decoding machinery , 2007, Nature Reviews Genetics.